FILE 'HOME' ENTERED AT 10:37:22 ON 02 DEC 2012

=> file medline polymer embase biosis
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	0.24

FILE 'MEDLINE' ENTERED AT 10:37:47 ON 02 DEC 2012

FILE 'APOLLIT' COULD NOT BE ENTERED

FILE 'CAPLUS' ENTERED AT 10:37:47 ON 02 DEC 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' COULD NOT BE ENTERED

FILE 'CIN' ENTERED AT 10:37:47 ON 02 DEC 2012
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2012 American Chemical Society (ACS)

FILE 'COMPENDEX' COULD NOT BE ENTERED

FILE 'DISSABS' ENTERED AT 10:37:47 ON 02 DEC 2012
COPYRIGHT (C) 2012 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'IFIPAT' ENTERED AT 10:37:47 ON 02 DEC 2012
COPYRIGHT (C) 2012 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' COULD NOT BE ENTERED

FILE 'PASCAL' COULD NOT BE ENTERED

FILE 'PQSCITECH' COULD NOT BE ENTERED

FILE 'RAPRA' COULD NOT BE ENTERED

FILE 'SCISEARCH' ENTERED AT 10:37:47 ON 02 DEC 2012
Copyright (c) 2012 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 10:37:47 ON 02 DEC 2012
CA INDEXING COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 10:37:47 ON 02 DEC 2012
CA INDEXING COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:37:47 ON 02 DEC 2012
CA INDEXING COPYRIGHT (C) 2012 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' COULD NOT BE ENTERED

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'WSCA' COULD NOT BE ENTERED

FILE 'EMBASE' ENTERED AT 10:37:47 ON 02 DEC 2012
Copyright (c) 2012 Elsevier B.V. All rights reserved.

```
FILE 'BIOSIS' ENTERED AT 10:37:47 ON 02 DEC 2012
Copyright (c) 2012 The Thomson Corporation

=> s

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):sss

L1       24164 SSS

=> s (liver(a) cancer) or (hepatic(a)cancer) or (hepatoma) or (liver(a)neoplas?)
L2      416609 (LIVER(A) CANCER) OR (HEPATIC(A) CANCER) OR (HEPATOMA) OR (LIVER
               (A) NEOPLAS?)

=> s l2 and treat?
  10 FILES SEARCHED...
L3      154206 L2 AND TREAT?

=> s l3 and ((MMDX) or (methoxymorpholino(a)doxorubicin))
L4          17 L3 AND ((MMDX) OR (METHOXYMORPHOLINO(A) DOXORUBICIN))

=> dis l4 1-17 bib abs

L4   ANSWER 1 OF 17  USPATFULL on STN
AN     2012:146072  USPATFULL <<LOGINID::20121202>>
TI     ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND
       THEIR USE AS ANTITUMOR COMPOUNDS
IN     Beria, Italo, Milan, ITALY
       Caruso, Michele, Milan, ITALY
       Flygare, John A., Burlingame, CA, UNITED STATES
       Lupi, Vittoria, Milan, ITALY
       Perego, Rita, Milan, ITALY
       Polakis, Paul, Mill Valley, CA, UNITED STATES
       Polson, Andrew, San Francisco, CA, UNITED STATES
       Salsa, Matteo, Novara, ITALY
       Spencer, Susan D., Mill Valley, CA, UNITED STATES
       Valsasina, Barbara, Milan, ITALY
PI     US 20120130059      A1  20120524
AI     US 2012-360212      A1  20120127 (13)
RLI    Continuation of Ser. No. US 2009-502433, filed on 14 Jul 2009, PENDING
PRAI   US 2008-80944P          20080715 (61)
DT     Utility
FS     APPLICATION
CLMN   Number of Claims: 18
ECL    Exemplary Claim: 1
DRWN   27 Drawing Page(s)
LN.CNT 5014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to conjugates of therapeutically useful
       anthracyclines with carriers such as polyclonal and monoclonal
       antibodies, proteins or peptides of natural or synthetic origin; methods
       for their preparation, pharmaceutical composition containing them and
       use thereof in treating certain mammalian tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 2 OF 17  USPATFULL on STN
AN     2011:85885  USPATFULL <<LOGINID::20121202>>
TI     NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND
       METHODS
IN     Cohen, Robert L, San Mateo, CA, UNITED STATES
       Ha, Edward HyungSuk, San Francisco, CA, UNITED STATES
```

Reynolds, Mark E., Millbrae, CA, UNITED STATES
PI US 20110076287 A1 20110331
AI US 2009-865354 A1 20090116 (12)
WO 2009-US31199 20090116
20101130 PCT 371 date
PRAI US 2008-25504P 20080201 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibody-drug conjugate compounds of Formula I:

Ab-(L-D).sub.p I

where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 17 USPATFULL on STN
AN 2010:39175 USPATFULL <<LOGINID::20121202>>
TI ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS
IN Beria, Italo, Milan, ITALY
Caruso, Michele, Milan, ITALY
Flygare, John A., Burlingame, CA, UNITED STATES
Lupi, Vittoria, Milan, ITALY
Perego, Rita, Milan, ITALY
Polakis, Paul, Mill Valley, CA, UNITED STATES
Polson, Andrew, San Francisco, CA, UNITED STATES
Salsa, Matteo, Novara, ITALY
Spencer, Susan D., Mill Valley, CA, UNITED STATES
Valsasina, Barbara, Milan, ITALY
PI US 20100034837 A1 20100211
AI US 2009-502433 A1 20090714 (12)
PRAI US 2008-80944P 20080715 (61)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 5462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 17 USPATFULL on STN
AN 2004:247248 USPATFULL <<LOGINID::20121202>>

TI Cell-killing molecules and methods of use thereof
IN Wright, Susan C., Saratoga, CA, UNITED STATES
Larrick, James W., Woodside, CA, UNITED STATES
Wilson, David S., Mountain View, CA, UNITED STATES
Nock, Steffen R., Redwood City, CA, UNITED STATES
PA Palo Alto Institute of Molecular Medicine (U.S. corporation)
PI US 20040191843 A1 20040930
AI US 2004-770668 A1 20040202 (10)
PRAI US 2003-444191P 20030203 (60)
US 2003-460855P 20030408 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA,
94105
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 7872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising amino acid sequences that have cell killing activity, nucleic acid sequences encoding them, antibodies that specifically bind with them, and methods of using these compositions for increasing and/or reducing cell death, detecting cell death, diagnosing diseases associated with altered cell death, and methods for identifying test agents that alter cell death.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 17 USPATFULL on STN
AN 2003:127624 USPATFULL <<LOGINID::20121202>>
TI Combined preparations comprising morpholine anthracyclines and anticancer agent
IN Geroni, Maria Christina, Milan, ITALY
Ripamonti, Marina, Milan, ITALY
Caruso, Michele, Milan, ITALY
Suarato, Antonino, Milan, ITALY
PA PHARMACIA & UPJOHN S.p.A, Milan, ITALY (non-U.S. corporation)
PI US 20030087839 A1 20030508
US 6586428 B2 20030701
AI US 2002-284144 A1 20021031 (10)
RLI Continuation of Ser. No. US 2001-926392, filed on 25 Oct 2001, PENDING A 371 of International Ser. No. WO 2000-EP2923, filed on 4 Apr 2000, UNKNOWN
PRAI GB 1999-9925 19990429
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET,
ALEXANDRIA, VA, 22314
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an allylating agent, an antimetabolite, a topoisomerase II inihbitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly

in the treatment of a primary or metastatic liver cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 17 USPATFULL on STN
AN 2003:81733 USPATFULL <<LOGINID::20121202>>
TI Combined preparations comprising morpholine anthracyclines and anticancer agent
IN Geroni, Maria Cristina, Milan, ITALY
Ripamonti, Marina, Milan, ITALY
Caruso, Michele, Milan, ITALY
Suarato, Antonino, Milan, ITALY
PA Pharmacia Italia S.p.A., Nerviano, ITALY (non-U.S. corporation)
PI US 6537990 B1 20030325
WO 9948503 19990930
AI US 2001-926392 20011025 (9)
WO 2000-EP2923 20000404
PRAI GB 1999-9925 19990429
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Anderson, Rebecca
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 17 USPATFULL on STN
AN 2002:282968 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
PA Battelle Pulmonary Therapeutics, Inc., Columbus, OH, United States (U.S. corporation)
PI US 6471943 B1 20021029
AI US 1997-775 19971230 (9)
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Wiesmann, Klaus H.
CLMN Number of Claims: 81
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 17 USPATFULL on STN
AN 2002:279635 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, UNITED STATES
Imondi, Anthony R., Westerville, OH, UNITED STATES
Brooker, Michael J., Westerville, OH, UNITED STATES
Frye, John E., Groveport, OH, UNITED STATES
Shah, Praful K., Hilliard, OH, UNITED STATES
Flanagan, Douglas R., JR., Iowa City, IA, UNITED STATES
Donovan, Maureen D., Solon, IA, UNITED STATES
PI US 2002155066 A1 20021024
AI US 2002-66831 A1 20020204 (10)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS APPLICATION
LREP Battelle Pulmonary Therapeutics, Inc., Suite 100, 1801 Watermark Drive, Columbus, OH, 43215-1037
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 17 USPATFULL on STN
AN 2002:239008 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Grandview, OH, United States
Imondi, Anthony R., Westerville, OH, United States
Shah, Praful K., Hilliard, OH, United States
PA BattellePharma, Inc., Columbus, OH, United States (U.S. corporation)
PI US 6451784 B1 20020917
AI US 2000-517915 20000303 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Pryor, Alton
LREP Coburn, Patricia A., Wiesmann, Klaus H.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and method for treating neoplasms such as cancer by administering a pharmaceutically effective amount or carboplatin by inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 17 USPATFULL on STN
AN 2002:106455 USPATFULL <<LOGINID::20121202>>
TI Compositions and methods for treating disease utilizing a combination

of radioactive therapy and cell-cycle inhibitors
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Loss, Troy A.E., North Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PI US 20020055666 A1 20020509
AI US 2001-865195 A1 20010524 (9)
RLI Continuation-in-part of Ser. No. US 2000-712047, filed on 13 Nov 2000, PENDING
PRAI US 1999-165259P 19991112 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 357
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 9469
AB Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor

L4 ANSWER 11 OF 17 USPATFULL on STN
AN 2001:199727 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
Brooker, Michael J., Westerville, OH, United States
Frye, John E., Groveport, OH, United States
Shah, Praful K., Hilliard, OH, United States
Flanagan, Douglas R., JR., Iowa City, IA, United States
Donovan, Maureen D., Solon, IA, United States
PI US 20010038827 A1 20011108
US 6348209 B2 20020219
AI US 2001-875680 A1 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS APPLICATION
LREP BATTELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 17 USPATFULL on STN
AN 2001:199726 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States

Brooker, Michael J., Westerville, OH, United States
Frye, John E., Groveport, OH, United States
Shah, Praful K., Hilliard, OH, United States
Flanagan, Douglas R., JR., Iowa City, IA, United States
Donovan, Maureen D., Solon, IA, United States
PI US 20010038826 A1 20011108
US 6419900 B2 20020716
AI US 2001-875345 A1 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS APPLICATION
LREP BATTELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 17 USPATFULL on STN
AN 2001:193931 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
Brooker, Michael J., Westerville, OH, United States
Frye, John E., Groveport, OH, United States
Shah, Praful K., Hilliard, OH, United States
Flanagan, Douglas R., JR., Iowa City, IA, United States
Donovan, Maureen D., Solon, IA, United States
PI US 20010036444 A1 20011101
US 6419901 B2 20020716
AI US 2001-875677 A1 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS APPLICATION
LREP BATTELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 17 USPAT2 on STN
AN 2003:127624 USPAT2 <<LOGINID::20121202>>
TI Combined preparations comprising morpholine anthracyclines and anticancer agent
IN Geroni, Maria Cristina, Milan, ITALY
Ripamonti, Marina, Milan, ITALY

Caruso, Michele, Milan, ITALY
Suarato, Antonino, Milan, ITALY
PA Pharmacia Italia, S.p.A., Milan, ITALY (non-U.S. corporation)
PI US 6586428 B2 20030701
AI US 2002-284144 20021031 (10)
RLI Continuation of Ser. No. US 926392
PRAI GB 1999-9925 19990426
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Anderson, Rebecca
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inihbitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 17 USPAT2 on STN
AN 2001:199727 USPAT2 <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
Brooker, Michael J., Westerville, OH, United States
Frye, John E., Groveport, OH, United States
Shah, Praful K., Hilliard, OH, United States
Flanagan, Jr., Douglas R., Iowa City, IA, United States
Donovan, Maureen D., Solon, IA, United States
PA Battelle Pulmonary Therapeutics, Inc., Columbus, OH, United States (U.S. corporation)
PI US 6348209 B2 20020219
AI US 2001-875680 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Bennett, Rachel M.
LREP Coburn, Patricia A.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2393
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 17 USPAT2 on STN
AN 2001:199726 USPAT2 <<LOGINID::20121202>>

```
TI     Formulation and method for treating neoplasms by inhalation
IN     Placke, Michael E., Columbus, OH, United States
       Imondi, Anthony R., Westerville, OH, United States
PA     Battelle Pulmonary Therapeutics, Columbus, OH, United States (U.S.
       corporation)
PI     US 6419900          B2  20020716
AI     US 2001-875345          20010606 (9)
RLI    Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI   US 1996-33789P          19961230 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Spear, James M.; Assistant Examiner: Bennett, Rachel
       M.
LREP   Coburn, Patricia A., Wiesmann, Klaus
CLMN   Number of Claims: 24
ECL    Exemplary Claim: 1
DRWN   7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A formulation, method, and apparatus for treating neoplasms such as
       cancer by administering a pharmaceutically effective amount of highly
       toxic composition by inhalation, wherein the composition is a
       non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 17 OF 17  USPAT2 on STN
AN     2001:193931  USPAT2 <<LOGINID::20121202>>
TI     Method for treating neoplasms by inhalation
IN     Placke, Michael E., Columbus, OH, United States
       Imondi, Anthony R., Westerville, OH, United States
PA     Battelle Pulmonary Therapeutics, Columbus, OH, United States (U.S.
       corporation)
PI     US 6419901          B2  20020716
AI     US 2001-875677          20010606 (9)
RLI    Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI   US 1996-33789P          19961230 (60)
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Page, Thurman K.; Assistant Examiner: Bennett, Rachel
       M.
LREP   Coburn, Patricia A., Wiesmann, Klaus
CLMN   Number of Claims: 24
ECL    Exemplary Claim: 1
DRWN   7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A formulation, method, and apparatus for treating neoplasms such as
       cancer by administering a pharmaceutically effective amount of highly
       toxic composition by inhalation, wherein the composition is a
       non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s ((MMDX) or (methoxymorpholino(a)doxorubicin))
L5         267 ((MMDX) OR (METHOXYMORPHOLINO(A) DOXORUBICIN))

=> s l5 and tumor
L6         215 L5 AND TUMOR
```

```
=> s l6 and liver
L7          140 L6 AND LIVER

=> s l7 and lipiodol
L8            3 L7 AND LIPIODOL

=> dis l7 and metasta?
'AND' IS NOT A VALID FORMAT
'METASTA?' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files.  Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> s l7 and metasta?
L9          104 L7 AND METASTA?

=> dis l9 1-104 bib abs

L9   ANSWER 1 OF 104     MEDLINE ®  on STN
AN   2000322685     MEDLINE <<LOGINID::20121202>>
DN   PubMed ID: 10866316
TI   In vivo antitumor activity and host toxicity of methoxymorpholinyl
     doxorubicin: role of cytochrome P450 3A.
AU   Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
CS   Department of Oncology and Surgical Sciences, University of Padova, Italy.
     lquintie@ux1.unipd.it
SO   Cancer research, (2000 Jun 15) Vol. 60, No. 12, pp. 3232-8.
     Journal code: 2984705R. ISSN: 0008-5472. L-ISSN: 0008-5472.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA   English
FS   Priority Journals
EM   200007
ED   Entered STN: 28 Jul 2000
     Last Updated on STN: 28 Jul 2000
     Entered Medline: 20 Jul 2000
OSC.G 1       There are 1 MEDLINE records that cite this record
AB   Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a promising
     doxorubicin derivative currently undergoing clinical evaluation.  Previous
     in vitro studies suggested that the compound undergoes hepatic
     biotransformation by cytochrome P450 (CYP) 3A into a more cytotoxic
     metabolite(s).  The present study examined the role of CYP3A-mediated
     metabolism in the in vivo antitumor activity and host toxicity of MMDX
     in the mouse model and investigated the potential for increasing the
     therapeutic effectiveness of the drug by inducing its hepatic
     CYP-catalyzed activation.  We found that MMDX cytotoxicity for cultured
     M5076 tumor cells was potentiated 22-fold by preincubating the drug with
     NADPH-supplemented liver microsomes from untreated C57BL/6 female mice.
     A greater (50-fold) potentiation of MMDX cytotoxicity was observed after
     its preincubation with liver microsomes isolated from animals pretreated
     with the prototypical CYP3A inducer pregnenolone-16alpha-carbonitrile.  In
     contrast, in vivo administration of the selective CYP3A inhibitor
     troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and
     the rate of CYP3A-catalyzed N-demethylation of erythromycin by isolated
     liver microsomes (55.5 and 49% reduction, respectively).  In vivo
     antitumor activity experiments revealed that TAO completely suppressed the
     ability of 90 microg/kg MMDX i.v., a dose close to the LD10, to delay
     growth of s.c.  M5076 tumors in C57BL/6 mice and to prolong survival of
```

DBA/2 mice with disseminated L1210 leukemia. Moreover, TAO administration markedly inhibited the therapeutic efficacy of 90 microg/kg MMDX i.v. in mice bearing experimental M5076 liver metastases; a complete loss of MMDX activity was observed in liver metastases-bearing animals receiving 40 microg/kg MMDX i.v. plus TAO. However, pregnenolone-16alpha-carbonitrile pretreatment failed to enhance MMDX activity in mice bearing either s.c. M5076 tumors or experimental M5076 liver metastases. Additional experiments carried out in healthy C57BL/6 mice showed that TAO markedly inhibited MMDX-induced myelosuppression and protected the animals against lethal doses of MMDX. Taken together, these findings demonstrate that an active metabolite(s) of MMDX synthesized via CYP3A contributes significantly to its in vivo antitumor activity and host toxicity.

L9 ANSWER 2 OF 104 MEDLINE ® on STN
AN 1999196374 MEDLINE <<LOGINID::20121202>>
DN PubMed ID: 10098738
TI Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases.
AU Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Zanovello P; Collavo D
CS Department of Oncology and Surgical Sciences, University of Padova, Italy.
SO British journal of cancer, (1999 Mar) Vol. 79, No. 7-8, pp. 1067-73.
Journal code: 0370635. ISSN: 0007-0920. L-ISSN: 0007-0920.
Report No.: NLM-PMC2362260.
CY SCOTLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 199904
ED Entered STN: 26 Apr 1999
Last Updated on STN: 26 Apr 1999
Entered Medline: 13 Apr 1999
REM.CNT 16 There are 16 cited references available in MEDLINE for this document.
AB The possibility of using interleukin 2 (IL-2)-activated natural killer cells (A-NK) to carry methoxymorpholinyl doxorubicin (MMDX; PNU 152243) to liver-infiltrating tumours was explored in mice bearing 2-day established M5076 reticulum cell sarcoma hepatic metastases. In vitro, MMDX was 5.5-fold more potent than doxorubicin against M5076 tumour cells. MMDX uptake by A-NK cells correlated linearly with drug concentration in the incubation medium [correlation coefficient (r) = 0.999]; furthermore, as MMDX incorporation was readily reproducible in different experiments, the amount of drug delivered by A-NK cells could be modulated. In vivo experiments showed that intravenous (i.v.) injection of MMDX-loaded A-NK cells exerted a greater therapeutic effect than equivalent or even higher doses of free drug. The increase in lifespan (ILS) following A-NK cell delivery of 53 microg kg(-1) MMDX, a dosage that is ineffective when administered in free form, was similar to that observed in response to 92 microg kg(-1) free drug, a dosage close to the 10% lethal dose (ILS 42% vs. 38% respectively). These results correlated with pharmacokinetic studies showing that MMDX encapsulation in A-NK cells strongly modifies its organ distribution and targets it to tissues in which IL-2 activated lymphocytes are preferentially entrapped after i.v. injection.

L9 ANSWER 3 OF 104 CAPLUS COPYRIGHT 2012 ACS on STN
AN 2000:438786 CAPLUS <<LOGINID::20121202>>
DN 133:144561
TI In vivo antitumor activity and host toxicity of methoxymorpholinyl

doxorubicin: role of cytochrome P450 3A
AU Quintieri, Luigi; Rosato, Antonio; Napoli, Eleonora; Sola, Francesco; Geroni, Cristina; Floreani, Maura; Zanovello, Paola
CS Oncology Section, Department of Oncology and Surgical Sciences, University of Padova, Padua, 35128, Italy
SO Cancer Research (2000), 60(12), 3232-3238
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a promising doxorubicin derivative currently undergoing clin. evaluation. Previous in vitro studies suggested that the compound undergoes hepatic biotransformation by cytochrome P 450 (CYP) 3A into a more cytotoxic metabolite(s). The present study examined the role of CYP3A-mediated metabolism in the in vivo antitumor activity and host toxicity of MMDX in the mouse model and investigated the potential for increasing the therapeutic effectiveness of the drug by inducing its hepatic CYP-catalyzed activation. We found that MMDX cytotoxicity for cultured M5076 tumor cells was potentiated 22-fold by preincubating the drug with NADPH-supplemented liver microsomes from untreated C57BL/6 female mice. A greater (50-fold) potentiation of MMDX cytotoxicity was observed after its preincubation with liver microsomes isolated from animals pretreated with the prototypical CYP3A inducer pregnenolone-16α-carbonitrile. In contrast, in vivo administration of the selective CYP3A inhibitor troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and the rate of CYP3A-catalyzed N-demethylation of erythromycin by isolated liver microsomes (55.5 and 49% reduction, resp.). In vivo antitumor activity expts. revealed that TAO completely suppressed the ability of 90 μg/kg MMDX i.v., a dose close to the LD10, to delay growth of s.c. M5076 tumors in C57BL/6 mice and to prolong survival of DBA/2 mice with disseminated L1210 leukemia. Moreover, TAO administration markedly inhibited the therapeutic efficacy of 90 μg/kg MMDX i.v. in mice bearing exptl. M5076 liver metastases; a complete loss of MMDX activity was observed in liver metastases-bearing animals receiving 40 μg/kg MMDX i.v. plus TAO. However, pregnenolone-16α-carbonitrile pretreatment failed to enhance MMDX activity in mice bearing either s.c. M5076 tumors or exptl. M5076 liver metastases. Addnl. expts. carried out in healthy C57BL/6 mice showed that TAO markedly inhibited MMDX-induced myelosuppression and protected the animals against LDs of MMDX. Taken together, these findings demonstrate that an active metabolite(s) of MMDX synthesized via CYP3A contributes significantly to its in vivo antitumor activity and host toxicity.
OSC.G 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 104 CAPLUS COPYRIGHT 2012 ACS on STN
AN 1999:186967 CAPLUS <<LOGINID::20121202>>
DN 131:39313
TI Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases
AU Quintieri, L.; Rosato, A.; Amboldi, N.; Vizler, C.; Ballinari, D.; Zanovello, P.; Collavo, D.
CS Department of Oncology and Surgical Sciences, University of Padova, Padua, 35128, Italy
SO British Journal of Cancer (1999), 79(7/8), 1067-1073
CODEN: BJCAAI; ISSN: 0007-0920
PB Churchill Livingstone

DT Journal
LA English
AB The possibility of using interleukin 2 (IL-2)-activated natural killer cells (A-NK) to carry methoxymorpholinyl doxorubicin (MMDX; PNU 152243) to liver-infiltrating tumors was explored in mice bearing 2-day established M5076 reticulum cell sarcoma hepatic metastases. In vitro, MMDX was 5.5-fold more potent than doxorubicin against M5076 tumor cells. MMDX uptake by A-NK cells correlated linearly with drug concentration in the incubation medium [correlation coefficient (r) = 0.999]; furthermore, as MMDX incorporation was readily reproducible in different expts., the amount of drug delivered by A-NK cells could be modulated. In vivo expts. showed that i.v. injection of MMDX-loaded A-NK cells exerted a greater therapeutic effect than equivalent or even higher doses of free drug. The increase in lifespan (ILS) following A-NK cell delivery of 53 μg kg-1 MMDX, a dosage that is ineffective when administered in free form, was similar to that observed in response to 92 μg kg-1 free drug, a dosage close to the 10% LD (ILS 42% vs. 38%, resp.). These results correlated with pharmacokinetic studies showing that MMDX encapsulation in A-NK cells strongly modifies its organ distribution and targets it to tissues in which IL-2-activated lymphocytes are preferentially entrapped after i.v. injection.
OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 104 CAPLUS COPYRIGHT 2012 ACS on STN
AN 1998:87389 CAPLUS <<LOGINID::20121202>>
DN 128:200684
OREF 128:39519a,39522a
TI Broad phase II and pharmacokinetic study of methoxymorpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumor patients
AU Bakker, M.; Droz, J. P.; Hanauske, A. R.; Verweij, J.; Van Oosterom, A. T.; Groen, H. J. M.; Pacciarini, M. A.; Domenigoni, L.; Van Weissenbruch, F.; Pianezzola, E.; De Vries, E. G. E.
CS University Hospital Groningen, Groningen, 9700 RB, Neth.
SO British Journal of Cancer (1998), 77(1), 139-146
CODEN: BJCAAI; ISSN: 0007-0920
PB Churchill Livingstone
DT Journal
LA English
AB The aim was to perform a broad phase II and pharmacokinetic study of methoxymorpholino-doxorubicin (MMRDX), a drug active against multidrug-resistant tumor cells in vitro when given by i.v. bolus at 1.5 mg m-2 every 4 wk, in metastatic or unresectable solid tumor patients with known intrinsic drug resistance. Patients received a maximum of six cycles. Plasma, urine and leukocyte MMRDX and its 13-dihydro metabolite pharmacokinetic anal. was performed in patients without liver metastases. Patients (n = 48, 21 NSCLC, 19 renal cell, three head and neck tumor, three cervical cancer and two adenocarcinoma of unknown primary) received 132 cycles of MMRDX. Common toxicity criteria (CTC) grade III/IV thrombocytopenia (12% of cycles) and neutropenia (27% of cycles) occurred with median nadir on day 22. Transient transaminases elevation ≥ grade III/IV was observed in 7% of cycles, late and prolonged nausea ≥ grade II in 34% and vomiting ≥ grade II in 39%. In two patients, the left ventricular ejection fraction was reduced ≥ 15%. Of 37 evaluable patients, one out of 17 NSCLC had a partial response. Mean (± s.d.) MMRDX AUC0-∞ calculated up to 24 h after dosing was 20.4 ± 6.2 μg h l-1 (n = 11) and t1/2' γ was 44.2 h. Mean plasma clearance (± s.d.) was 37.2 ± 7.3 l h-1 m-2 and volume of distribution 1982 ± 64 l m-2. MMRDX leukocyte levels 2 and

24 h after infusion were 450 to 600-fold higher than corresponding MMRDX plasma levels. In urine, 2% of the MMRDX dose was excreted unchanged, and 2% as metabolite. The main side-effects of 1.5 mg m-2 every 4 wk of MMRDX are delayed nausea and vomiting and haematol. toxicity. MMRDX is characterized by extensive clearance and rapid and extensive distribution into tissues. A low response rate was observed in patients with tumors with intrinsic chemotherapy resistance.

OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 104 SCISEARCH COPYRIGHT (c) 2012 The Thomson Corporation on STN
AN 2000:464536 SCISEARCH <<LOGINID::20121202>>
GA The Genuine Article (R) Number: 325EZ
TI In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: Role of cytochrome P450 3A
AU Quintieri L (Reprint)
CS Univ Padua, Dept Oncol & Surg Sci, Oncol Sect, Via Gattamelata 64, I-35128
Padua, Italy (Reprint)
AU Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
CS Univ Padua, Dept Oncol & Surg Sci, Oncol Sect, I-35128 Padua, Italy; Univ
Padua, Dept Pharmacol, Padua, Italy; Pharmacia & Upjohn Inc, Dept
Discovery Res Oncol, I-20014 Nerviano, Italy
CYA Italy
SO CANCER RESEARCH, (15 JUN 2000) Vol. 60, No. 12, pp. 3232-3238.
ISSN: 0008-5472.
PB AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL 35202 USA.
DT Article; Journal
LA English
REC Reference Count: 48
ED Entered STN: 2000
Last Updated on STN: 2000
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a promising doxorubicin derivative currently undergoing clinical evaluation. Previous in vitro studies suggested that the compound undergoes hepatic biotransformation by cytochrome p450 (CYP) 3A into a more cytotoxic metabolite(s). The present study examined the role of CYP3A-mediated metabolism in the in vivo antitumor activity and host toxicity of MMDX in the mouse model and investigated the potential for increasing the therapeutic effectiveness of the drug by inducing its hepatic CYP-catalyzed activation, We Found that MMDX cytotoxicity for cultured M5076 tumor cells was potentiated 22-fold by preincubating the drug with NADPH-supplemented liver microsomes from untreated C57BL/6 female mice. A greater (50-fold) potentiation of MMDX cytotoxicity was observed after its preincubation with liver microsomes isolated from animals pretreated with the prototypical CYP3A inducer pregnenolone-16 alpha-carbonitrile. In contrast, in vivo administration of the selective CYP3A inhibitor troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and the rate of CYP3A-catalyzed,N-demethylation of erythromycin by isolated liver microsomes (55.5 and 49% reduction, respectively). In vivo antitumor activity experiments revealed that TAO completely suppressed the ability of 90 mu g/kg MMDX i.v,. a dose close to the LD10, to delay growth of s,c, M5076 rumors in C57BL/6 mice and to prolong survival of DBA/2 mice with disseminated L1210 leukemia. Moreover, TAO administration markedly, inhibited the therapeutic efficacy of 90 mu g/kg MMDX i.v. in mice bearing experimental M5076 liver metastases; a complete loss of

MMDX activity was observed in Liver metastases-bearing animals receiving 40 mu g/kg MMDX i,v. plus TAO, However, pregnenolone-16 alpha-carbonitrile pretreatment failed to enhance MMDX activity in mice bearing either s.c. M5076 tumors or experimental M5076 liver metastases. Additional experiments tarried out in healthy C57BL/6 mice showed that TAO markedly inhibited MMDX-induced myelosuppression and protected the animals against lethal doses of MMDX. Taken together, these findings demonstrate that an active metabolite(s) of MMDX synthesized via CYP3A contributes significantly to its in vivo antitumor activity and host toxicity.

L9 ANSWER 7 OF 104 SCISEARCH COPYRIGHT (c) 2012 The Thomson Corporation on STN
AN 1999:137982 SCISEARCH <<LOGINID::20121202>>
GA The Genuine Article (R) Number: 168NQ
TI Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases
AU Zanovello P (Reprint)
CS Univ Padua, Dept Oncol & Surg Sci, Chair Immunol, Via Gattamelata 64, I-35128 Padua, Italy (Reprint)
AU Quintieri L; Rosato A; Amboldi N; Vizler C; Ballinari D; Collavo D
CS Univ Padua, Dept Oncol & Surg Sci, Chair Immunol, I-35128 Padua, Italy; Pharmacia & Upjohn Inc, Discovery Res Oncol, I-20014 Nerviano, MI, Italy
CYA Italy
SO BRITISH JOURNAL OF CANCER, (MAR 1999) Vol. 79, No. 7-8, pp. 1067-1073. ISSN: 0007-0920.
PB CHURCHILL LIVINGSTONE, JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND.
DT Article; Journal
LA English
REC Reference Count: 19
ED Entered STN: 1999
Last Updated on STN: 1999
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB The possibility of using interleukin 2 (IL-2)-activated natural killer cells (A-NK) to carry methoxymorpholinyl doxorubicin (MMDX; PNU 152243) to liver-infiltrating tumours was explored in mice bearing 2-day established M5076 reticulum cell sarcoma hepatic metastases, In vitro, MMDX was 5.5-fold more potent than doxorubicin against M5076 tumour cells. MMDX uptake by A-NK cells correlated linearly with drug concentration in the incubation medium [correlation coefficient (r) = 0.999]; furthermore, as MMDX incorporation was readily reproducible in different experiments, the amount of drug delivered by A-NK cells could be modulated. In vivo experiments showed that intravenous (i.v.) injection of MMDX-loaded A-NK cells exerted a greater therapeutic effect than equivalent or even higher doses of free drug. The increase in lifespan (ILS) following A-NK cell delivery of 53 mu g kg(-1) MMDX, a dosage that is ineffective when administered in free form, was similar to that observed in response to 92 mu g kg(-1) free drug, a dosage close to the 10% lethal dose (ILS 42% vs. 38% respectively). These results correlated with pharmacokinetic studies showing that MMDX encapsulation in A-NK cells strongly modifies its organ distribution and targets it to tissues in which IL-2 activated lymphocytes are preferentially entrapped after i.v. injection.

L9 ANSWER 8 OF 104 USPATFULL on STN
AN 2012:283597 USPATFULL <<LOGINID::20121202>>
TI DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION

IN Gravett, David M., Mountain View, CA, UNITED STATES
Takacs-Cox, Aniko, North Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Embree, Leanne, Squamish, CANADA
PA ANGIOTECH INTERNATIONAL AG (U.S. corporation)
PI US 20120252905 A1 20121004
AI US 2012-461424 A1 20120501 (13)
RLI Continuation of Ser. No. US 2008-259916, filed on 28 Oct 2008, ABANDONED
Continuation of Ser. No. US 2003-749117, filed on 30 Dec 2003, ABANDONED
PRAI US 2002-437471P 20021230 (60)
US 2003-440875P 20030117 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-126
DRWN 8 Drawing Page(s)
LN.CNT 4793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 104 USPATFULL on STN
AN 2012:146072 USPATFULL <<LOGINID::20121202>>
TI ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS
IN Beria, Italo, Milan, ITALY
Caruso, Michele, Milan, ITALY
Flygare, John A., Burlingame, CA, UNITED STATES
Lupi, Vittoria, Milan, ITALY
Perego, Rita, Milan, ITALY
Polakis, Paul, Mill Valley, CA, UNITED STATES
Polson, Andrew, San Francisco, CA, UNITED STATES
Salsa, Matteo, Novara, ITALY
Spencer, Susan D., Mill Valley, CA, UNITED STATES
Valsasina, Barbara, Milan, ITALY
PI US 20120130059 A1 20120524
AI US 2012-360212 A1 20120127 (13)
RLI Continuation of Ser. No. US 2009-502433, filed on 14 Jul 2009, PENDING
PRAI US 2008-80944P 20080715 (61)
DT Utility
FS APPLICATION
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 5014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 104 USPATFULL on STN
AN 2012:58385 USPATFULL <<LOGINID::20121202>>
TI POLYMER COMPOSITIONS AND METHODS FOR THEIR USE
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravelt, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
Guan, Dechi, Vancouver, CANADA
Wang, Kaiyue, Burnaby, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20120052040 A1 20120301
AI US 2011-69258 A1 20110322 (13)
RLI Continuation of Ser. No. US 2004-1790, filed on 2 Dec 2004, ABANDONED
Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, ABANDONED
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 33999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 104 USPATFULL on STN
AN 2012:46388 USPATFULL <<LOGINID::20121202>>
TI COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE
IN Daniloff, George Y., Mountain View, CA, UNITED STATES
Sehl, Louis C., Redwood City, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
Gravett, David M., Palo Alto, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
PA AngioDevice International GmbH, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20120041481 A1 20120216
AI US 2011-279987 A1 20111024 (13)
RLI Continuation of Ser. No. US 2005-118088, filed on 28 Apr 2005, Pat. No. US 8067031
PRAI US 2004-566569P 20040428 (60)
DT Utility
FS APPLICATION

CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 7568
AB Kits comprising dry power compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The dry powder composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked biomaterials include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

L9 ANSWER 12 OF 104 USPATFULL on STN
AN 2012:44898 USPATFULL <<LOGINID::20121202>>
TI COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE
IN Daniloff, George Y., Mountain View, CA, UNITED STATES
Sehl, Louis C., Redwood City, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
Gravett, David M., Palo Alto, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
PA , ANGIODEVICE INTERNATIONAL GMBH, Zug, SWITZERLAND (U.S. individual)
PI US 20120039980 A1 20120216
AI US 2011-279982 A1 20111024 (13)
RLI Division of Ser. No. US 2005-118088, filed on 28 Apr 2005, Pat. No. US 8067031
PRAI US 2004-566569P 20040428 (60)
DT Utility
FS APPLICATION
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 7566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 104 USPATFULL on STN
AN 2011:85885 USPATFULL <<LOGINID::20121202>>
TI NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS
IN Cohen, Robert L, San Mateo, CA, UNITED STATES
Ha, Edward HyungSuk, San Francisco, CA, UNITED STATES
Reynolds, Mark E., Millbrae, CA, UNITED STATES
PI US 20110076287 A1 20110331
AI US 2009-865354 A1 20090116 (12)
WO 2009-US31199 20090116
20101130 PCT 371 date
PRAI US 2008-25504P 20080201 (61)
DT Utility

FS APPLICATION
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibody-drug conjugate compounds of Formula I:

Ab-(L-D).sub.p I

where one or more nemorubicin metabolite or analog drug moieties (D) are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 104 USPATFULL on STN
AN 2010:301276 USPATFULL <<LOGINID::20121202>>
TI ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20100268288 A1 20101021
AI US 2010-703679 A1 20100210 (12)
RLI Continuation of Ser. No. US 2004-998351, filed on 26 Nov 2004, ABANDONED Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14692
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 15 OF 104 USPATFULL on STN
AN 2010:103970 USPATFULL <<LOGINID::20121202>>
TI IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20100092536 A1 20100415

AI US 2009-464012 A1 20090511 (12)
RLI Continuation of Ser. No. US 2004-1789, filed on 1 Dec 2004, ABANDONED Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14999
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 104 USPATFULL on STN
AN 2010:39175 USPATFULL <<LOGINID::20121202>>
TI ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS
IN Beria, Italo, Milan, ITALY
Caruso, Michele, Milan, ITALY
Flygare, John A., Burlingame, CA, UNITED STATES
Lupi, Vittoria, Milan, ITALY
Perego, Rita, Milan, ITALY
Polakis, Paul, Mill Valley, CA, UNITED STATES
Polson, Andrew, San Francisco, CA, UNITED STATES
Salsa, Matteo, Novara, ITALY
Spencer, Susan D., Mill Valley, CA, UNITED STATES
Valsasina, Barbara, Milan, ITALY
PI US 20100034837 A1 20100211
AI US 2009-502433 A1 20090714 (12)
PRAI US 2008-80944P 20080715 (61)
DT Utility
FS APPLICATION
LREP GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 5462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 104 USPATFULL on STN
AN 2009:252633 USPATFULL <<LOGINID::20121202>>
TI SUTURES AND ANTI-SCARRING AGENTS
IN Avelar, Rui, Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Cashman, Johanne Diane, Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
PA Angiotech Pharmaceuticals, Inc, Vancouver, CANADA (non-U.S. corporation)
PI US 20090226500 A1 20090910
AI US 2007-162572 A1 20070131 (12)
WO 2007-US2714 20070131
20090506 PCT 371 date
PRAI US 2006-763945P 20060131 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1-35
DRWN 29 Drawing Page(s)
LN.CNT 9064
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sutures are used in combination with anti-scarring agents to inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are described for use in reducing excessive scarring, surgical adhesion, and other disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 104 USPATFULL on STN
AN 2009:239288 USPATFULL <<LOGINID::20121202>>
TI SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Mountain View, CA, UNITED STATES
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20090214652 A1 20090827
AI US 2009-425316 A1 20090416 (12)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, ABANDONED Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, ABANDONED
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 12543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in

order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 104 USPATFULL on STN
AN 2009:213938 USPATFULL <<LOGINID::20121202>>
TI DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION
IN Gravett, David M., Mountain View, CA, UNITED STATES
Takacs-Cox, Aniko, North Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Embree, Leanne, Squamish, CANADA
PA ANGIOTECH INTERNATIONAL AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20090192214 A1 20090730
AI US 2008-259916 A1 20081028 (12)
RLI Continuation of Ser. No. US 2003-749117, filed on 30 Dec 2003, ABANDONED
PRAI US 2003-440875P 20030117 (60)
US 2002-437471P 20021230 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1-126
DRWN 8 Drawing Page(s)
LN.CNT 4793
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 104 USPATFULL on STN
AN 2008:66658 USPATFULL <<LOGINID::20121202>>
TI Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Loss, Troy A. E., North Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20080058579 A1 20080306
AI US 2006-594022 A1 20061106 (11)
RLI Continuation of Ser. No. US 2002-155868, filed on 24 May 2002, ABANDONED Continuation-in-part of Ser. No. US 2001-865195, filed on 24 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-712047, filed on 13 Nov 2000, ABANDONED
PRAI US 1999-165259P 19991112 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENUE, SUITE 5400, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 8686
AB Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor

L9 ANSWER 21 OF 104 USPATFULL on STN
AN 2007:342045 USPATFULL <<LOGINID::20121202>>
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070299043 A1 20071227
AI US 2007-732808 A1 20070404 (11)
RLI Continuation-in-part of Ser. No. US 2006-542185, filed on 3 Oct 2006, PENDING
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 37332
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 104 USPATFULL on STN
AN 2007:237758 USPATFULL <<LOGINID::20121202>>
TI Anti-scarring drug combinations and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES

PI US 20070208134 A1 20070906
AI US 2006-542185 A1 20061003 (11)
PRAI US 2005-723053P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 37771
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 104 USPATFULL on STN
AN 2007:225962 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring drug combinations
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070198063 A1 20070823
AI US 2006-542163 A1 20061003 (11)
PRAI US 2005-723637P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 24469
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 24 OF 104 USPATFULL on STN
AN 2007:225856 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors, implantable pumps and anti-scarring drug combinations
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES

Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070197957 A1 20070823
AI US 2006-542101 A1 20061003 (11)
PRAI US 2005-723638P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 24410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 25 OF 104 USPATFULL on STN
AN 2007:224324 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and drug combination compositions, and use thereof
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Grau, Daniel S., Arlington, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Serbedzija, George N., Sudbury, MA, UNITED STATES
PI US 20070196421 A1 20070823
AI US 2006-542211 A1 20061003 (11)
PRAI US 2005-723601P 20051003 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 22161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 104 USPATFULL on STN
AN 2006:328918 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20060282123 A1 20061214
AI US 2004-6910 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2264
DRWN 32 Drawing Page(s)
LN.CNT 14774
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 27 OF 104 USPATFULL on STN
AN 2006:174046 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20060147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 56233
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent,

e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 104 USPATFULL on STN
AN 2005:323977 USPATFULL <<LOGINID::20121202>>
TI Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
IN Daniloff, George Y., Mountain View, CA, UNITED STATES
Sehl, Louis C., Redwood City, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PI US 20050281883 A1 20051222
US 8067031 B2 20111129
AI US 2005-118088 A1 20050428 (11)
PRAI US 2004-566569P 20040428 (60)
DT Utility
FS APPLICATION
LREP REED INTELLECTUAL PROPERTY LAW GROUP, 1400 PAGE MILL ROAD, PALO ALTO, CA, 94304-1124, US
CLMN Number of Claims: 349
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 8347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 104 USPATFULL on STN
AN 2005:241661 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209666 A1 20050922
AI US 2004-6885 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-630
DRWN 32 Drawing Page(s)
LN.CNT 14772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 104 USPATFULL on STN
AN 2005:241660 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209665 A1 20050922
AI US 2004-998351 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-11691
DRWN 32 Drawing Page(s)
LN.CNT 14777
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 31 OF 104 USPATFULL on STN
AN 2005:241659 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050209664 A1 20050922
AI US 2004-998349 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586471P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1377
DRWN 32 Drawing Page(s)
LN.CNT 14786
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 32 OF 104 USPATFULL on STN
AN 2005:240095 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 101
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 34089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 33 OF 104 USPATFULL on STN
AN 2005:234693 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050203635 A1 20050915
AI US 2004-6909 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3038
DRWN 32 Drawing Page(s)
LN.CNT 12596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 34 OF 104 USPATFULL on STN
AN 2005:226572 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 35 OF 104 USPATFULL on STN
AN 2005:221910 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050192647 A1 20050901
AI US 2004-6898 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1992
DRWN 32 Drawing Page(s)
LN.CNT 14794
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 36 OF 104 USPATFULL on STN
AN 2005:220596 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
    Gravett, David M., Vancouver, CANADA
    Toleikis, Philip M., Vancouver, CANADA
    Maiti, Arpita, Vancouver, CANADA
    Signore, Pierre E., Vancouver, CANADA
    Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050191331 A1 20050901
AI US 2004-1419 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
    US 2003-523908P 20031120 (60)
    US 2003-524023P 20031120 (60)
    US 2003-525226P 20031124 (60)
    US 2003-526541P 20031203 (60)
    US 2004-586861P 20040709 (60)
    US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-2104
DRWN 28 Drawing Page(s)
LN.CNT 56419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 37 OF 104 USPATFULL on STN
AN 2005:215962 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
    Gravett, David M., Vancouver, CANADA
    Toleikis, Philip M., Vancouver, CANADA
    Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050187639 A1 20050825
AI US 2004-6892 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov

2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-3470
DRWN 32 Drawing Page(s)
LN.CNT 12657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 38 OF 104 USPATFULL on STN
AN 2005:215923 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050187600 A1 20050825
AI US 2004-998350 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3352
DRWN 32 Drawing Page(s)
LN.CNT 14781
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 39 OF 104 USPATFULL on STN
AN 2005:215464 USPATFULL <<LOGINID::20121202>>

TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050187140 A1 20050825
AI US 2004-408 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2004-611077P 20040917 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-5846
DRWN 32 Drawing Page(s)
LN.CNT 34103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 40 OF 104 USPATFULL on STN
AN 2005:214574 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186246 A1 20050825
AI US 2004-6883 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-2606
DRWN 32 Drawing Page(s)
LN.CNT 12658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 41 OF 104 USPATFULL on STN
AN 2005:214573 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186245 A1 20050825
AI US 2004-6880 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2785
DRWN 32 Drawing Page(s)
LN.CNT 15059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 42 OF 104 USPATFULL on STN
AN 2005:214572 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050186244 A1 20050825
AI US 2004-1790 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-8540
DRWN 32 Drawing Page(s)
LN.CNT 34060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 43 OF 104 USPATFULL on STN
AN 2005:214567 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050186239 A1 20050825
AI US 2004-6897 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3058
DRWN 32 Drawing Page(s)
LN.CNT 15050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 44 OF 104 USPATFULL on STN
AN 2005:212068 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050183731 A1 20050825
AI US 2004-6908 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1-8061
DRWN 32 Drawing Page(s)
LN.CNT 34032
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 45 OF 104 USPATFULL on STN
AN 2005:212065 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050183728 A1 20050825
AI US 2004-7836 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-3411
DRWN 28 Drawing Page(s)
LN.CNT 56413
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L9 ANSWER 46 OF 104 USPATFULL on STN
AN 2005:210011 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182496 A1 20050818
AI US 2004-6906 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3902
DRWN 32 Drawing Page(s)
LN.CNT 12588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 47 OF 104 USPATFULL on STN

AN 2005:209984 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050182469 A1 20050818
AI US 2004-7837 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 120
ECL Exemplary Claim: 1-2803
DRWN 32 Drawing Page(s)
LN.CNT 14838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 48 OF 104 USPATFULL on STN
AN 2005:209983 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182468 A1 20050818
AI US 2004-6891 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1720
DRWN 32 Drawing Page(s)
LN.CNT 14768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 49 OF 104 USPATFULL on STN
AN 2005:209982 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182467 A1 20050818
AI US 2004-6884 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1168
DRWN 32 Drawing Page(s)
LN.CNT 14785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 50 OF 104 USPATFULL on STN
AN 2005:209978 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050182463 A1 20050818
AI US 2004-1788 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 125
ECL Exemplary Claim: 1-8059
DRWN 32 Drawing Page(s)
LN.CNT 34070
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 51 OF 104 USPATFULL on STN
AN 2005:209965 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050182450 A1 20050818
AI US 2004-6890 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-349
DRWN 32 Drawing Page(s)
LN.CNT 14792
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L9 ANSWER 52 OF 104 USPATFULL on STN
AN 2005:209494 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
    Gravett, David M., Vancouver, CANADA
    Toleikis, Philip M., Vancouver, CANADA
    Maiti, Arpita, Vancouver, CANADA
    Signore, Pierre E., Vancouver, CANADA
    Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181977 A1 20050818
AI US 2004-986231 A1 20041110 (10)
PRAI US 2003-518785P 20031110 (60)
    US 2003-523908P 20031120 (60)
    US 2003-524023P 20031120 (60)
    US 2003-525226P 20031124 (60)
    US 2003-526541P 20031203 (60)
    US 2004-586861P 20040709 (60)
    US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 182
ECL Exemplary Claim: 1
DRWN 28 Drawing Page(s)
LN.CNT 56396
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 53 OF 104 USPATFULL on STN
AN 2005:208533 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
    Gravett, David M., Vancouver, CANADA
    Toleikis, Philip M., Vancouver, CANADA
    Maiti, Arpita, Vancouver, CANADA
    Signore, Pierre E., Vancouver, CANADA
    Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
    US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 177
ECL Exemplary Claim: 1-4994
DRWN 28 Drawing Page(s)
LN.CNT 56421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 54 OF 104 USPATFULL on STN
AN 2005:208532 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181010 A1 20050818
AI US 2004-1789 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-296
DRWN 32 Drawing Page(s)
LN.CNT 15014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to

inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 55 OF 104 USPATFULL on STN
AN 2005:208531 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181009 A1 20050818
AI US 2004-1787 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1-570
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 56 OF 104 USPATFULL on STN
AN 2005:208530 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181008 A1 20050818
AI US 2004-1786 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-4736
DRWN 28 Drawing Page(s)
LN.CNT 56377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 57 OF 104 USPATFULL on STN
AN 2005:208529 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050181007 A1 20050818
AI US 2004-1415 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 126
ECL Exemplary Claim: 1-444
DRWN 32 Drawing Page(s)
LN.CNT 12675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 58 OF 104 USPATFULL on STN
AN 2005:208527 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050181005 A1 20050818
AI US 2004-6901 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2510
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 59 OF 104 USPATFULL on STN
AN 2005:205930 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050178396 A1 20050818
AI US 2004-6905 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1-8063
DRWN 32 Drawing Page(s)
LN.CNT 33965
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 60 OF 104 USPATFULL on STN
AN 2005:205929 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050178395 A1 20050818
AI US 2004-6900 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1-7302
DRWN 32 Drawing Page(s)
LN.CNT 34043
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L9 ANSWER 61 OF 104 USPATFULL on STN
AN 2005:203799 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
PI US 20050177225 A1 20050811
AI US 2004-6895 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 173
ECL Exemplary Claim: 1-11788
DRWN 28 Drawing Page(s)
LN.CNT 56371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 62 OF 104 USPATFULL on STN
AN 2005:202285 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175703 A1 20050811
AI US 2004-6888 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1-7576
DRWN 32 Drawing Page(s)
LN.CNT 33992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 63 OF 104 USPATFULL on STN
AN 2005:202247 USPATFULL <<LOGINID::20121202>>
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175665 A1 20050811
AI US 2004-6896 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1-7822
DRWN 32 Drawing Page(s)
LN.CNT 33978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 64 OF 104 USPATFULL on STN
AN 2005:202246 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175664 A1 20050811
AI US 2004-4672 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-851
DRWN 32 Drawing Page(s)
LN.CNT 15038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 65 OF 104 USPATFULL on STN
AN 2005:202245 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050175663 A1 20050811
AI US 2004-1791 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 180
ECL Exemplary Claim: 1-3944
DRWN 28 Drawing Page(s)
LN.CNT 56451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed

within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 66 OF 104 USPATFULL on STN
AN 2005:195820 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050169961 A1 20050804
AI US 2004-4675 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 118
ECL Exemplary Claim: 1-1941
DRWN 32 Drawing Page(s)
LN.CNT 15063
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 67 OF 104 USPATFULL on STN
AN 2005:195819 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 20050169960 A1 20050804
AI US 2004-4671 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1-3328
DRWN 32 Drawing Page(s)
LN.CNT 15057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 68 OF 104 USPATFULL on STN
AN 2005:190568 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)
PI US 20050165488 A1 20050728
AI US 2004-6912 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 176
ECL Exemplary Claim: 1-3153
DRWN 28 Drawing Page(s)
LN.CNT 56407
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic

connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L9 ANSWER 69 OF 104 USPATFULL on STN
AN 2005:182973 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050158356 A1 20050721
AI US 2004-996352 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 15058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 70 OF 104 USPATFULL on STN
AN 2005:178293 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vacouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050154374 A1 20050714
AI US 2004-6882 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2240
DRWN 32 Drawing Page(s)
LN.CNT 15052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 71 OF 104 USPATFULL on STN
AN 2005:176868 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152948 A1 20050714
AI US 2004-7838 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-2174
DRWN 32 Drawing Page(s)
LN.CNT 12627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 72 OF 104 USPATFULL on STN
AN 2005:176867 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152947 A1 20050714
AI US 2004-6903 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1742
DRWN 32 Drawing Page(s)
LN.CNT 12637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 73 OF 104 USPATFULL on STN
AN 2005:176866 USPATFULL <<LOGINID::20121202>>
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152946 A1 20050714
AI US 2004-6894 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1126
DRWN 32 Drawing Page(s)
LN.CNT 15056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are

implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 74 OF 104 USPATFULL on STN
AN 2005:176865 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152945 A1 20050714
AI US 2004-6887 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1310
DRWN 32 Drawing Page(s)
LN.CNT 12592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 75 OF 104 USPATFULL on STN
AN 2005:176864 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152944 A1 20050714
AI US 2004-6881 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-878
DRWN 32 Drawing Page(s)
LN.CNT 12628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 76 OF 104 USPATFULL on STN
AN 2005:176861 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050152941 A1 20050714
AI US 2004-996353 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 132
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 12685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 77 OF 104 USPATFULL on STN
AN 2005:172409 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149158 A1 20050707

AI US 2004-409 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-274
DRWN 28 Drawing Page(s)
LN.CNT 56404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 78 OF 104 USPATFULL on STN
AN 2005:172408 USPATFULL <<LOGINID::20121202>>
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149157 A1 20050707
AI US 2004-996355 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 111
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 14769

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 79 OF 104 USPATFULL on STN
AN 2005:172331 USPATFULL <<LOGINID::20121202>>
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050149080 A1 20050707
AI US 2004-1418 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-806
DRWN 28 Drawing Page(s)
LN.CNT 56418
AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L9 ANSWER 80 OF 104 USPATFULL on STN
AN 2005:164738 USPATFULL <<LOGINID::20121202>>
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20050142162 A1 20050630

AI US 2004-1416 A1 20041201 (11)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-524023P 20031120 (60)
US 2003-523908P 20031120 (60)
US 2003-525226P 20031124 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1-4334
DRWN 32 Drawing Page(s)
LN.CNT 12679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 81 OF 104 USPATFULL on STN
AN 2004:328492 USPATFULL <<LOGINID::20121202>>
TI Anastomotic connector devices
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20040260318 A1 20041223
AI US 2004-853023 A1 20040524 (10)
PRAI US 2003-473185P 20030523 (60)
US 2003-523908P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 117
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 6906
AB Anastomotic connector devices are provided which release a therapeutic agent. The therapeutic agent may be an anti-scarring agent that inhibits stenosis caused by the presence of the anastomotic connector device.

L9 ANSWER 82 OF 104 USPATFULL on STN
AN 2004:286909 USPATFULL <<LOGINID::20121202>>
TI Drug delivery from rapid gelling polymer composition
IN Gravett, David M., Vancouver, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Embree, Leanne, Squamish, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.

corporation)
PI US 20040225077 A1 20041111
AI US 2003-749117 A1 20031230 (10)
PRAI US 2003-440875P 20030117 (60)
US 2002-437471P 20021230 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 126
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 5102
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 83 OF 104 USPATFULL on STN
AN 2004:279914 USPATFULL <<LOGINID::20121202>>
TI Tissue reactive compounds and compositions and uses thereof
IN Gravett, David M., Vancouver, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Embree, Leanne, Squamish, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 20040219214 A1 20041104
AI US 2003-749123 A1 20031230 (10)
PRAI US 2003-440924P 20030117 (60)
US 2002-437384P 20021230 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 240
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 5170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 84 OF 104 USPATFULL on STN
AN 2004:247248 USPATFULL <<LOGINID::20121202>>

TI Cell-killing molecules and methods of use thereof
IN Wright, Susan C., Saratoga, CA, UNITED STATES
Larrick, James W., Woodside, CA, UNITED STATES
Wilson, David S., Mountain View, CA, UNITED STATES
Nock, Steffen R., Redwood City, CA, UNITED STATES
PA Palo Alto Institute of Molecular Medicine (U.S. corporation)
PI US 20040191843 A1 20040930
AI US 2004-770668 A1 20040202 (10)
PRAI US 2003-444191P 20030203 (60)
US 2003-460855P 20030408 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA,
94105
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 7872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions comprising amino acid sequences that have cell killing activity, nucleic acid sequences encoding them, antibodies that specifically bind with them, and methods of using these compositions for increasing and/or reducing cell death, detecting cell death, diagnosing diseases associated with altered cell death, and methods for identifying test agents that alter cell death.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 85 OF 104 USPATFULL on STN
AN 2003:208209 USPATFULL <<LOGINID::20121202>>
TI Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Loss, Troy A.E., North Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA Angiotech Pharmaceuticals, Inc., Vancouver, BC, CANADA, V6T 1Z4 (non-U.S. corporation)
PI US 20030144570 A1 20030731
AI US 2002-155868 A1 20020524 (10)
RLI Continuation-in-part of Ser. No. US 2001-865195, filed on 24 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-712047, filed on 13 Nov 2000, PENDING
PRAI US 1999-165259P 19991112 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 8668
AB Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor

L9 ANSWER 86 OF 104 USPATFULL on STN
AN 2003:127624 USPATFULL <<LOGINID::20121202>>
TI Combined preparations comprising morpholine anthracyclines and anticancer agent
IN Geroni, Maria Christina, Milan, ITALY
Ripamonti, Marina, Milan, ITALY
Caruso, Michele, Milan, ITALY
Suarato, Antonino, Milan, ITALY
PA PHARMACIA & UPJOHN S.p.A, Milan, ITALY (non-U.S. corporation)
PI US 20030087839 A1 20030508
US 6586428 B2 20030701
AI US 2002-284144 A1 20021031 (10)
RLI Continuation of Ser. No. US 2001-926392, filed on 25 Oct 2001, PENDING A 371 of International Ser. No. WO 2000-EP2923, filed on 4 Apr 2000, UNKNOWN
PRAI GB 1999-9925 19990429
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an allylating agent, an antimetabolite, a topoisomerase II inihbitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 87 OF 104 USPATFULL on STN
AN 2003:81733 USPATFULL <<LOGINID::20121202>>
TI Combined preparations comprising morpholine anthracyclines and anticancer agent
IN Geroni, Maria Cristina, Milan, ITALY
Ripamonti, Marina, Milan, ITALY
Caruso, Michele, Milan, ITALY
Suarato, Antonino, Milan, ITALY
PA Pharmacia Italia S.p.A., Nerviano, ITALY (non-U.S. corporation)
PI US 6537990 B1 20030325
WO 9948503 19990930
AI US 2001-926392 20011025 (9)
WO 2000-EP2923 20000404
PRAI GB 1999-9925 19990429
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Anderson, Rebecca
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combined preparations comprising a

morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inhibitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 88 OF 104 USPATFULL on STN
AN 2002:282968 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
PA Battelle Pulmonary Therapeutics, Inc., Columbus, OH, United States (U.S. corporation)
PI US 6471943 B1 20021029
AI US 1997-775 19971230 (9)
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Wiesmann, Klaus H.
CLMN Number of Claims: 81
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 89 OF 104 USPATFULL on STN
AN 2002:279635 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, UNITED STATES
Imondi, Anthony R., Westerville, OH, UNITED STATES
Brooker, Michael J., Westerville, OH, UNITED STATES
Frye, John E., Groveport, OH, UNITED STATES
Shah, Praful K., Hilliard, OH, UNITED STATES
Flanagan, Douglas R., JR., Iowa City, IA, UNITED STATES
Donovan, Maureen D., Solon, IA, UNITED STATES
PI US 20020155066 A1 20021024
AI US 2002-66831 A1 20020204 (10)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS APPLICATION
LREP Battelle Pulmonary Therapeutics, Inc., Suite 100, 1801 Watermark Drive, Columbus, OH, 43215-1037
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 90 OF 104 USPATFULL on STN
AN 2002:239008 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Grandview, OH, United States
Imondi, Anthony R., Westerville, OH, United States
Shah, Praful K., Hilliard, OH, United States
PA BattellePharma, Inc., Columbus, OH, United States (U.S. corporation)
PI US 6451784 B1 20020917
AI US 2000-517915 20000303 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Pryor, Alton
LREP Coburn, Patricia A., Wiesmann, Klaus H.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and method for treating neoplasms such as cancer by administering a pharmaceutically effective amount or carboplatin by inhalation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 91 OF 104 USPATFULL on STN
AN 2002:106455 USPATFULL <<LOGINID::20121202>>
TI Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Loss, Troy A.E., North Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PI US 20020055666 A1 20020509
AI US 2001-865195 A1 20010524 (9)
RLI Continuation-in-part of Ser. No. US 2000-712047, filed on 13 Nov 2000, PENDING
PRAI US 1999-165259P 19991112 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
CLMN Number of Claims: 357
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 9469
AB Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor

L9 ANSWER 92 OF 104 USPATFULL on STN
AN 2001:199727 USPATFULL <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation

```
IN     Placke, Michael E., Columbus, OH, United States
       Imondi, Anthony R., Westerville, OH, United States
       Brooker, Michael J., Westerville, OH, United States
       Frye, John E., Groveport, OH, United States
       Shah, Praful K., Hilliard, OH, United States
       Flanagan, Douglas R., JR., Iowa City, IA, United States
       Donovan, Maureen D., Solon, IA, United States
PI     US 20010038827      A1  20011108
       US 6348209          B2  20020219
AI     US 2001-875680      A1  20010606 (9)
RLI    Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI   US 1996-33789P          19961230 (60)
DT     Utility
FS     APPLICATION
LREP   BATTELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693
CLMN   Number of Claims: 127
ECL    Exemplary Claim: 1
DRWN   6 Drawing Page(s)
LN.CNT 2807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A formulation, method, and apparatus for treating neoplasms such as
       cancer by administering a pharmaceutically effective amount of highly
       toxic composition by inhalation, wherein the composition is a
       non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 93 OF 104  USPATFULL on STN
AN     2001:199726  USPATFULL <<LOGINID::20121202>>
TI     Formulation and method for treating neoplasms by inhalation
IN     Placke, Michael E., Columbus, OH, United States
       Imondi, Anthony R., Westerville, OH, United States
       Brooker, Michael J., Westerville, OH, United States
       Frye, John E., Groveport, OH, United States
       Shah, Praful K., Hilliard, OH, United States
       Flanagan, Douglas R., JR., Iowa City, IA, United States
       Donovan, Maureen D., Solon, IA, United States
PI     US 20010038826      A1  20011108
       US 6419900          B2  20020716
AI     US 2001-875345      A1  20010606 (9)
RLI    Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI   US 1996-33789P          19961230 (60)
DT     Utility
FS     APPLICATION
LREP   BATTELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693
CLMN   Number of Claims: 127
ECL    Exemplary Claim: 1
DRWN   6 Drawing Page(s)
LN.CNT 2813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A formulation, method, and apparatus for treating neoplasms such as
       cancer by administering a pharmaceutically effective amount of highly
       toxic composition by inhalation, wherein the composition is a
       non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 94 OF 104  USPATFULL on STN
AN     2001:193931  USPATFULL <<LOGINID::20121202>>
TI     Formulation and method for treating neoplasms by inhalation
IN     Placke, Michael E., Columbus, OH, United States
```

Imondi, Anthony R., Westerville, OH, United States
Brooker, Michael J., Westerville, OH, United States
Frye, John E., Groveport, OH, United States
Shah, Praful K., Hilliard, OH, United States
Flanagan, Douglas R., JR., Iowa City, IA, United States
Donovan, Maureen D., Solon, IA, United States
PI US 20010036444 A1 20011101
US 6419901 B2 20020716
AI US 2001-875677 A1 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997, PENDING
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS APPLICATION
LREP BATTELLE MEMORIAL INSTITUTE, 505 KING AVENUE, COLUMBUS, OH, 43201-2693
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 2810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 95 OF 104 USPAT2 on STN
AN 2005:323977 USPAT2 <<LOGINID::20121202>>
TI Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
IN Daniloff, George Y., Mountain View, CA, UNITED STATES
Sehl, Louis C., Redwood City, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PA AngioDevice International GmbH, Zug, SWITZERLAND (non-U.S. corporation)
PI US 8067031 B2 20111129
AI US 2005-118088 20050428 (11)
PRAI US 2004-566569P 20040428 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Krass, Frederick; Assistant Examiner: Sutton, Darryl C
LREP Seed IP Law Group PLLC
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 7719
AB Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury.

L9 ANSWER 96 OF 104 USPAT2 on STN
AN 2003:127624 USPAT2 <<LOGINID::20121202>>
TI Combined preparations comprising morpholine anthracyclines and anticancer agent
IN Geroni, Maria Cristina, Milan, ITALY
Ripamonti, Marina, Milan, ITALY
Caruso, Michele, Milan, ITALY
Suarato, Antonino, Milan, ITALY
PA Pharmacia Italia, S.p.A., Milan, ITALY (non-U.S. corporation)
PI US 6586428 B2 20030701
AI US 2002-284144 20021031 (10)
RLI Continuation of Ser. No. US 926392
PRAI GB 1999-9925 19990426
DT Utility
FS GRANTED
EXNAM Primary Examiner: McKane, Joseph K.; Assistant Examiner: Anderson, Rebecca
LREP McDonnell Boehnen Hulbert & Berghoff
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 476
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to combined preparations comprising a morpholinyl anthracycline administered in combination anticancer agents chosen from an alkylating agent, an antimetabolite, a topoisomerase II inihbitor, a topoisomerase I inhibitor, an antimitotic drug and a platinum derivative, which are useful anticancer therapy, particularly in the treatment of a primary or metastatic liver cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 97 OF 104 USPAT2 on STN
AN 2001:199727 USPAT2 <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
Brooker, Michael J., Westerville, OH, United States
Frye, John E., Groveport, OH, United States
Shah, Praful K., Hilliard, OH, United States
Flanagan, Jr., Douglas R., Iowa City, IA, United States
Donovan, Maureen D., Solon, IA, United States
PA Battelle Pulmonary Therapeutics, Inc., Columbus, OH, United States (U.S. corporation)
PI US 6348209 B2 20020219
AI US 2001-875680 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Bennett, Rachel M.
LREP Coburn, Patricia A.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2393
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly

toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 98 OF 104 USPAT2 on STN
AN 2001:199726 USPAT2 <<LOGINID::20121202>>
TI Formulation and method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
PA Battelle Pulmonary Therapeutics, Columbus, OH, United States (U.S. corporation)
PI US 6419900 B2 20020716
AI US 2001-875345 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spear, James M.; Assistant Examiner: Bennett, Rachel M.
LREP Coburn, Patricia A., Wiesmann, Klaus
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 99 OF 104 USPAT2 on STN
AN 2001:193931 USPAT2 <<LOGINID::20121202>>
TI Method for treating neoplasms by inhalation
IN Placke, Michael E., Columbus, OH, United States
Imondi, Anthony R., Westerville, OH, United States
PA Battelle Pulmonary Therapeutics, Columbus, OH, United States (U.S. corporation)
PI US 6419901 B2 20020716
AI US 2001-875677 20010606 (9)
RLI Continuation of Ser. No. US 1997-775, filed on 30 Dec 1997
PRAI US 1996-33789P 19961230 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Bennett, Rachel M.
LREP Coburn, Patricia A., Wiesmann, Klaus
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 7 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 100 OF 104 EMBASE COPYRIGHT (c) 2012 Elsevier B.V. All rights reserved on STN
AN 2000219020 EMBASE <<LOGINID::20121202>>
TI In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: Role of cytochrome P450 3A.
AU Quintieri, Luigi (correspondence)
CS Oncology Section, Dept. of Oncol. and Surg. Sciences, University of Padova, Via Gattamelata 64, 35128 Padova, Italy. lquintie@ux1.unipd.it
AU Quintieri, Luigi (correspondence); Rosato, Antonio; Zanovello, Paola
CS Oncology Section, Dept. of Oncol. and Surg. Sciences, University of Padova, 35128 Padova, Italy. lquintie@ux1.unipd.it
AU Napoli, Eleonora; Floreani, Maura
CS Department of Pharmacology, University of Padova, 35128 Padova, Italy.
AU Sola, Francesco; Geroni, Cristina
CS Pharmacia and Upjohn, Dept. of Discovery Research/Oncology, 20014 Nerviano, Italy.
AU Quintieri, Luigi (correspondence)
CS Oncology Section, Dept. of Oncology and Surg. Sciences, University of Padova, Via Gattamelata 64, 35128 Padova, Italy. lquintie@ux1.unipd.it
SO Cancer Research, (15 Jun 2000) Vol. 60, No. 12, pp. 3232-3238. Refs: 48
ISSN: 0008-5472 CODEN: CNREA8
CY United States
DT Journal; Article
FS 016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 13 Jul 2000
Last Updated on STN: 13 Jul 2000
AB Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a promising doxorubicin derivative currently undergoing clinical evaluation. Previous in vitro studies suggested that the compound undergoes hepatic biotransformation by cytochrome P450 (CYP) 3A into a more cytotoxic metabolite(s). The present study examined the role of CYP3A-mediated metabolism in the in vivo antitumor activity and host toxicity of MMDX in the mouse model and investigated the potential for increasing the therapeutic effectiveness of the drug by inducing its hepatic CYP-catalyzed activation. We found that MMDX cytotoxicity for cultured M5076 tumor cells was potentiated 22-fold by preincubating the drug with NADPH-supplemented liver microsomes from untreated C57BL/6 female mice. A greater (50-fold) potentiation of MMDX cytotoxicity was observed after its preincubation with liver microsomes isolated from animals pretreated with the prototypical CYP3A inducer pregnenolone-16α-carbonitrile. In contrast, in vivo administration of the selective CYP3A inhibitor troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and the rate of CYP3A-catalyzed N-demethylation of erythromycin by isolated liver microsomes (55.5 and 49% reduction, respectively). In vivo antitumor activity experiments revealed that TAO completely suppressed the ability of 90 μg/kg MMDX i.v., a dose close to the LD10, to delay growth of s.c. M5076 tumors in C57BL/6 mice and to prolong survival of DBA/2 mice with disseminated L1210 leukemia. Moreover, TAO administration markedly inhibited the therapeutic efficacy of 90 μg/kg MMDX i.v. in mice bearing experimental M5076 liver metastases; a complete loss of MMDX activity was observed in liver metastases-bearing animals receiving 40 μg/kg MMDX i.v. plus TAO. However, pregnenolone-16α-carbonitrile pretreatment failed to enhance MMDX activity in mice bearing either s.c, M5076 tumors or experimental M5076 liver metastases. Additional experiments carried out in healthy C57BL/6 mice showed that TAO markedly inhibited MMDX- induced

myelosuppression and protected the animals against lethal doses of MMDX. Taken together, these findings demonstrate that an active metabolite(s) of MMDX synthesized via CYP3A contributes significantly to its in vivo antitumor activity and host toxicity.

L9 ANSWER 101 OF 104 EMBASE COPYRIGHT (c) 2012 Elsevier B.V. All rights reserved on STN
AN 1998019753 EMBASE <<LOGINID::20121202>>
TI Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
AU Bakker, M.; Groen, H.J.M.; Van Weissenbruch, F.; De Vries, E.G.E. (correspondence)
CS University Hospital Groningen, Netherlands.
AU Droz, J.P.
CS Centre Leon Berard, Lyon, France.
AU Hanauske, A.R.
CS Med. Klinik und Poliklinik, TU, Munchen, Germany.
AU Verweij, J.
CS Rotterdam Cancer Institute, University Hospital, Rotterdam, Netherlands.
AU Van Oosterom, A.T.
CS University Hospital Leuven, Belgium.
AU Pacciarini, M.A.; Domenigoni, L.; Pianezzola, E.
CS Pharmacia, Milan, Italy.
AU De Vries, E.G.E. (correspondence)
CS Division of Medical Oncology, Department of Internal Medicine, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, Netherlands.
SO British Journal of Cancer, (1998) Vol. 77, No. 1, pp. 139-146.
Refs: 37
ISSN: 0007-0920 CODEN: BJCAAI
CY United Kingdom
DT Journal; Article
FS 015 Chest Diseases, Thoracic Surgery and Tuberculosis
016 Cancer
028 Urology and Nephrology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 2 Feb 1998
Last Updated on STN: 2 Feb 1998
AB The aim was to perform a broad phase II and pharmacokinetic study of methoxymorpholino-doxorubicin (MMRDX), a drug active against multidrug-resistant tumour cells in vitro when given by i.v. bolus at 1.5 mg m-2 every 4 weeks, in metastatic or unresectable solid tumour patients with known intrinsic drug resistance. Patients received a maximum of six cycles. Plasma, urine and leucocyte MMRDX and its 13-dihydro metabolite pharmacokinetic analysis was performed in patients without liver metastases. Patients (n = 48, 21 NSCLC, 19 renal cell, three head and neck tumour, three cervical cancer and two adenocarcinoma of unknown primary) received 132 cycles of MMRDX, Common toxicity criteria (CTC) grade III/IV thrombocytopenia (12% of cycles) and neutropenia (27% of cycles) occurred with median nadir on day 22. Transient transaminases elevation ≤ grade III/IV was observed in 7% of cycles, late and prolonged nausea ≤ grade II in 34% and vomiting ≤ grade II in 39%. In two patients, the left ventricular ejection fraction was reduced ≤ 15%. Of 37 evaluable patients, one out of 17 NSCLC had a partial response. Mean (± s.d.) MMRDX AUC(0→∞) calculated up to 24 h after dosing was 20.4 ± 6.2 μg h l-1 (n = 11) and t(1/2), (γ) was 44.2 h. Mean plasma clearance (± s.d.) was 37.2 ± 7.3 l h-1 m-2 and volume of distribution 1982 ± 64 l m-2. MMRDX leucocyte

levels 2 and 24 h after infusion were 450 to 600-fold higher than corresponding MMRDX plasma levels. In urine, 2% of the MMRDX dose was excreted unchanged, and 2% as metabolite. The main side-effects of 1.5 mg m-2 every 4 weeks of MMRDX are delayed nausea and vomiting and haematological toxicity. MMRDX is characterized by extensive clearance and rapid and extensive distribution into tissues. A low response rate was observed in patients with tumours with intrinsic chemotherapy resistance.

L9 ANSWER 102 OF 104 BIOSIS COPYRIGHT (c) 2012 The Thomson Corporation on STN
AN 2000:358367 BIOSIS <<LOGINID::20121202>>
DN PREV200000358367
TI In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: Role of cytochrome P450 3A.
AU Quintieri, Luigi [Reprint author]; Rosato, Antonio; Napoli, Eleonora; Sola, Francesco; Geroni, Cristina; Floreani, Maura; Zanovello, Paola
CS Oncology Section, Department of Oncology and Surgical Sciences, University of Padova, Via Gattamelata 64, 35128, Padova, Italy
SO Cancer Research, (June 15, 2000) Vol. 60, No. 12, pp. 3232-3238. print. CODEN: CNREA8. ISSN: 0008-5472.
DT Article
LA English
ED Entered STN: 16 Aug 2000
Last Updated on STN: 8 Jan 2002
AB Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a promising doxorubicin derivative currently undergoing clinical evaluation. Previous in vitro studies suggested that the compound undergoes hepatic biotransformation by cytochrome P450 (CYP) 3A into a more cytotoxic metabolite(s). The present study examined the role of CYP3A-mediated metabolism in the in vivo antitumor activity and host toxicity of MMDX in the mouse model and investigated the potential for increasing the therapeutic effectiveness of the drug by inducing its hepatic CYP-catalyzed activation. We found that MMDX cytotoxicity for cultured M5076 tumor cells was potentiated 22-fold by preincubating the drug with NADPH-supplemented liver microsomes from untreated C57BL/6 female mice. A greater (50-fold) potentiation of MMDX cytotoxicity was observed after its preincubation with liver microsomes isolated from animals pretreated with the prototypical CYP3A inducer pregnenolone-16alpha-carbonitrile. In contrast, in vivo administration of the selective CYP3A inhibitor troleandomycin (TAO) reduced both potentiation of MMDX cytotoxicity and the rate of CYP3A-catalyzed N-demethylation of erythromycin by isolated liver microsomes (55.5 and 49% reduction, respectively). In vivo antitumor activity experiments revealed that TAO completely suppressed the ability of 90 mug/kg MMDX i.v., a dose close to the LD10, to delay growth of s.c. M5076 tumors in C57L/6 mice and to prolong survival of DBA/2 mice with disseminated L1210 leukemia. Moreover, TAO administration markedly inhibited the therapeutic efficacy of 90 mug/kg MMDX i.v. in mice bearing experimental M5076 liver metastases; a complete loss of MMDX activity was observed in liver metastases-bearing animals receiving 40 mug/kg MMDX i.v. plus TAO. However, pregnenolone-16alpha-carbonitrile pretreatment failed to enhance MMDX activity in mice bearing either s.c. M5076 tumors or experimental M5076 liver metastases. Additional experiments carried out in healthy C57BL/6 mice showed that TAO markedly inhibited MMDX-induced myelosuppression and protected the animals against lethal doses of MMDX. Taken together, these findings demonstrate that an active metabolite(s) of MMDX synthesized via CYP3A contributes significantly to its in vivo antitumor activity and host toxicity.

L9 ANSWER 103 OF 104 BIOSIS COPYRIGHT (c) 2012 The Thomson Corporation on

STN
AN 1999:170385 BIOSIS <<LOGINID::20121202>>
DN PREV199900170385
TI Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: Effect in mice bearing hepatic metastases.
AU Quintieri, L.; Rosato, A.; Amboldi, N.; Vizler, C.; Ballinari, D.; Zanovello, P. [Reprint author]; Collavo, D.
CS Dep. Oncology Surgical Sciences, Univ. Padova, Via Gattamelata 64, 35128 Padova, Italy
SO British Journal of Cancer, (March, 1999) Vol. 79, No. 7-8, pp. 1067-1073. print.
CODEN: BJCAAI. ISSN: 0007-0920.
DT Article
LA English
ED Entered STN: 19 Apr 1999
Last Updated on STN: 19 Apr 1999
AB The possibility of using interleukin 2 (IL-2)-activated natural killer cells (A-NK) to carry methoxymorpholinyl doxorubicin (MMDX; PNU 152243) to liver-infiltrating tumours was explored in mice bearing 2-day established M5076 reticulum cell sarcoma hepatic metastases. In vitro, MMDX was 5.5-fold more potent than doxorubicin against M5076 tumour cells. MMDX uptake by A-NK cells correlated linearly with drug concentration in the incubation medium (correlation coefficient (r) = 0.999); furthermore, as MMDX incorporation was readily reproducible in different experiments, the amount of drug delivered by A-NK cells could be modulated. In vivo experiments showed that intravenous (i.v.) injection of MMDX-loaded A-NK cells exerted a greater therapeutic effect than equivalent or even higher doses of free drug. The increase in lifespan (ILS) following A-NK cell delivery of 53 mug kg-1 MMDX, a dosage that is ineffective when administered in free form, was similar to that observed in response to 92 mug kg-1 free drug, a dosage close to the 1 0% lethal dose (ILS 42% vs. 38% respectively). These results correlated with pharmacokinetic studies showing that MMDX encapsulation in A-NK cells strongly modifies its organ distribution and targets it to tissues in which IL-2 activated lymphocytes are preferentially entrapped after i.v. injection.

L9 ANSWER 104 OF 104 BIOSIS COPYRIGHT (c) 2012 The Thomson Corporation on STN
AN 1998:123896 BIOSIS <<LOGINID::20121202>>
DN PREV199800123896
TI Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
AU Bakker, M.; Droz, J. P.; Hanauske, A. R.; Verweij, J.; Van Oosterom, A. T.; Groen, H. J. M.; Pacciarini, M. A.; Domenigoni, L.; Van Weissenbruch, F.; Pianezzola, E.; De Vries, E. G. E. [Reprint author]
CS Div. Med. Oncol., Dep. Internal Med., Univ. Hosp. Groningen, PO Box 30.001, 9700 RB Groningen, Netherlands
SO British Journal of Cancer, (Jan., 1998) Vol. 77, No. 1, pp. 139-146. print.
CODEN: BJCAAI. ISSN: 0007-0920.
DT Article
LA English
ED Entered STN: 5 Mar 1998
Last Updated on STN: 6 Apr 1998
AB The aim was to perform a broad phase II and pharmacokinetic study of methoxymorpholino-doxorubicin (MMRDX), a drug active against multidrug-resistant tumour cells in vitro when given by i.v. bolus at 1.5 mg m-2 every 4 weeks, in metastatic or unresectable solid tumour patients with known intrinsic drug resistance. Patients received a

maximum of six cycles. Plasma, urine and leucocyte MMRDX and its 13-dihydro metabolite pharmacokinetic analysis was performed in patients without liver metastases. Patients (n = 48, 21 NSCLC, 19 renal cell, three head and neck tumour, three cervical cancer and two adenocarcinoma of unknown primary) received 132 cycles of MMRDX. Common toxicity criteria (CTC) grade III/IV thrombocytopenia (12% of cycles) and neutropenia (27% of cycles) occurred with median nadir on day 22. Transient transaminases elevation gtoreq grade III/IV was observed in 7% of cycles, late and prolonged nausea gtoreq grade II in 34% and vomiting gtoreq grade II in 39%. In two patients, the left ventricular ejection fraction was reduced gtoreq 15%. Of 37 evaluable patients, one out of 17 NSCLC had a partial response. Mean (+- s.d.) MMRDX AUC0-infin calculated up to 24 h after dosing was 20.4 +- 6.2 mug h l-1 (n = 11) and t1/2, gamma was 44.2 h. Mean plasma clearance (+- s.d.) was 37.2 +- 7.3 l h-1 m-2 and volume of distribution 1982 +- 64 l m-2. MMRDX leucocyte levels 2 and 24 h after infusion were 450 to 600-fold higher than corresponding MMRDX plasma levels. In urine, 2% of the MMRDX dose was excreted unchanged, and 2% as metabolite. The main side-effects of 1.5 mg m-2 every 4 weeks of MMRDX are delayed nausea and vomiting and haematological toxicity. MMRDX is characterized by extensive clearance and rapid and extensive distribution into tissues. A low response rate was observed in patients with tumours with intrinsic chemotherapy resistance.

=> dis hist

(FILE 'HOME' ENTERED AT 10:37:22 ON 02 DEC 2012)

FILE 'MEDLINE, CAPLUS, CIN, DISSABS, IFIPAT, SCISEARCH, USPATFULL, USPATOLD, USPAT2, EMBASE, BIOSIS' ENTERED AT 10:37:47 ON 02 DEC 2012

```
L1        24164 S
L2       416609 S (LIVER(A) CANCER) OR (HEPATIC(A)CANCER) OR (HEPATOMA) OR (LIV
L3       154206 S L2 AND TREAT?
L4           17 S L3 AND ((MMDX) OR (METHOXYMORPHOLINO(A)DOXORUBICIN))
L5          267 S ((MMDX) OR (METHOXYMORPHOLINO(A)DOXORUBICIN))
L6          215 S L5 AND TUMOR
L7          140 S L6 AND LIVER
L8            3 S L7 AND LIPIODOL
L9          104 S L7 AND METASTA?
```

=>